MYL : Analysis & Opinions

  1. Actavis to Appeal Ruling Regarding Namenda IR Sales - Analyst ...

    December 16, 2014
    Actavis plc (ACT) announced its decision to file an emergency appeal for an immediate overturn of the lower court ruling ...
  2. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  3. MedTech Defies Sequestration, M&As Steal the Show - Industry ...

    August 26, 2014
    MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
  4. 5 Drug Companies Profiting From Generics

    August 4, 2014
    Leading generic drug maker Teva Pharmaceutical (NYSE: TEVA) posted better-than-expected earnings last week and raised its ...
  5. Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry ...

    July 24, 2014
    Pharma, Biotech M&As Heat Up: Tax Inversion in Focus - Industry Outlook
  6. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  7. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  8. Valeant Eyes Bausch & Lomb

    May 28, 2013
    Canadian pharmaceutical company Valeant has made a name for itself through acquisitions. On May 27 it announced that it was ...
  9. A Good Deal For Actavis, But Warner Chilcott Goes A Little Cheap

    May 21, 2013
    Actavis gets a very useful asset, while Warner Chilcott shareholders get a decent exit.
  10. Teva Still Too Cheap, But Still Too Uncertain

    May 3, 2013
    Teva's present-day momentum is weak, but the value could appeal to patient long-term investors.
  11. Lannett Beats, Ups Guidance - Analyst Blog

    February 11, 2013
    Lannett Company, Inc. (LCI) reported second quarter fiscal 2013 earnings of 10 cents per share, above the Zacks Consensus ...
  12. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  13. Warner Chilcott Evenly Poised - Analyst Blog

    November 23, 2012
    We are maintaining our Neutral recommendation on Warner Chilcott plc (WCRX) with a target price of $12.00. The stock carries ...
  14. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  15. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  16. Shire Settles Patent Dispute - Analyst Blog

    September 12, 2012
    Shire LLC, a subsidiary of Shire plc (SHPG) recently announced that it has entered into a settlement agreement with Anchen ...
  17. Obama’s Corporate Tax Proposal: Which Companies Will Take A Hit?

    February 24, 2012
    President Obama has proposed corporate tax cuts that will lower corporate income taxes from 35% to 28%, but claims he willl ...
  18. "Dominant" Pattern Inspires 4 Buys

    February 1, 2012
    Reverse head-and-shoulders bottom formations in three stocks and an emerging market ETF are creating worthwhile buying opportunities ...
  19. Teva And Mylan Show Some Value Remains In Generics

    August 4, 2011
    These two generics companies seem to be heading in opposite directions, but the values are similar.
  20. 6 Overbought Stocks To Watch

    April 25, 2011
    Let's take a look at a few stocks that have recently entered overbought territory because these could be candidates for a ...
  21. Another Setback For Roche Is Bad News For ImmunoGen

    August 27, 2010
    Roche suffers another setback to its key cancer franchise, while ImmunoGen faces a major delay in royalty payments.
  22. Lilly's Top-Line Predicament

    April 21, 2010
    Eli Lilly will have more than $5 billion in annual free cash flow over the next few years to try and stem its top-line predicament. ...
  23. Convertible Securities On The Right Track

    September 11, 2009
    For those who need income but don’t want to miss out on moves in the overall market.
  24. Chico's Tops Companies With Insider Buying

    April 21, 2009
    When a company is trading near its high and has recent insider buying, it's definitely worth a closer look.
  25. Forest Labs Faces Patent Expirations

    January 23, 2009
    This pharma faces patent expirations on its two key drugs, but its valuation reflects these risks and the firm has appealing ...
  26. Meet Teva, The Generic Giant

    May 15, 2008
    Success in generic drugs is all about high volume, low prices and global presence. Israel's Teva Pharmaceuticals has all ...
Trading Center